Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
biomarkers
bone-vascular axis
cardiovascular disease
diabetic retinopathy
osteokines
type 2 diabetes
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
02
12
2022
received:
25
08
2022
accepted:
26
02
2023
medline:
10
7
2023
pubmed:
8
3
2023
entrez:
7
3
2023
Statut:
ppublish
Résumé
Novel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are compromised in diabetes. We aimed to evaluate possible associations of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease (CVD) and diabetic retinopathy (DR) among people with type 2 diabetes (T2D). Osteocalcin, osteoprotegerin, and osteopontin concentrations were measured at enrolment in 848 participants with T2D from the Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study (ClinicalTrials.gov: NCT02311244). Logistic regression models and propensity score matching were used to assess possible associations of osteocalcin, osteoprotegerin, and osteopontin with a history of CVD and with evidence of any grade of DR adjusting for confounders. Previous CVD was reported in 139 (16.4%) participants, while 144 (17.0%) had DR. After adjusting for possible confounders, osteocalcin but not osteoprotegerin or osteopontin concentrations were associated with a history of CVD (Odds Ratio [OR] and 95% CI for one standard deviation (SD) increase in osteocalcin concentrations (natural log): 1.35 (1.06-1.72), p = 0.014). Associations with prevalent DR were seen for osteoprotegerin (OR for one SD increase in osteoprotegerin concentrations (natural log): 1.25 (1.01-1.55), p = 0.047) and osteopontin (OR for one SD increase in osteopontin concentrations (natural log): 1.25 (1.02-1.53), p = 0.022), but not osteocalcin. In T2D, higher serum osteocalcin concentrations are associated with macrovascular complications and higher osteoprotegerin and osteopontin concentrations with microvascular complications, suggesting that these osteokines might be involved in pathways directly related to vascular disease.
Sections du résumé
BACKGROUND
BACKGROUND
Novel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are compromised in diabetes. We aimed to evaluate possible associations of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease (CVD) and diabetic retinopathy (DR) among people with type 2 diabetes (T2D).
MATERIALS AND METHODS
METHODS
Osteocalcin, osteoprotegerin, and osteopontin concentrations were measured at enrolment in 848 participants with T2D from the Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study (ClinicalTrials.gov: NCT02311244). Logistic regression models and propensity score matching were used to assess possible associations of osteocalcin, osteoprotegerin, and osteopontin with a history of CVD and with evidence of any grade of DR adjusting for confounders.
RESULTS
RESULTS
Previous CVD was reported in 139 (16.4%) participants, while 144 (17.0%) had DR. After adjusting for possible confounders, osteocalcin but not osteoprotegerin or osteopontin concentrations were associated with a history of CVD (Odds Ratio [OR] and 95% CI for one standard deviation (SD) increase in osteocalcin concentrations (natural log): 1.35 (1.06-1.72), p = 0.014). Associations with prevalent DR were seen for osteoprotegerin (OR for one SD increase in osteoprotegerin concentrations (natural log): 1.25 (1.01-1.55), p = 0.047) and osteopontin (OR for one SD increase in osteopontin concentrations (natural log): 1.25 (1.02-1.53), p = 0.022), but not osteocalcin.
CONCLUSIONS
CONCLUSIONS
In T2D, higher serum osteocalcin concentrations are associated with macrovascular complications and higher osteoprotegerin and osteopontin concentrations with microvascular complications, suggesting that these osteokines might be involved in pathways directly related to vascular disease.
Substances chimiques
Osteopontin
106441-73-0
Osteocalcin
104982-03-8
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02311244']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3632Subventions
Organisme : Sapienza Università di Roma
Organisme : Ministero della Salute
Organisme : European Foundation for the Study of Diabetes
Organisme : Fondazione Diabete Ricerca
Organisme : National Institute for Health Research
Investigateurs
Federica Alberico
(F)
Elena Alessi
(E)
Francesco Bagella
(F)
Ilaria Barchetta
(I)
Silvia Carletti
(S)
Tiziana Filardi
(T)
Giulia Leanza
(G)
Giacomo Marini
(G)
Pamela Piscitelli
(P)
Federica Sentinelli
(F)
Informations de copyright
© 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
Références
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3-16. https://doi.org/10.1007/s00125-018-4711-2
Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_Suppl l):25-32. https://doi.org/10.1177/2047487319878371
Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol. 2012;8(10):587-598. https://doi.org/10.1038/nrrheum.2012.120
D’Onofrio L, Maddaloni E, Buzzetti R. Osteocalcin and sclerostin: background characters or main actors in cardiovascular disease? Diabetes Metab Res Rev. 2020;36(1). https://doi.org/10.1002/DMRR.3217
Rashdan NA, Sim AM, Cui L, et al. Osteocalcin regulates arterial calcification via altered wnt signaling and glucose metabolism. J Bone Min Res. 2020;35(2):357-367. https://doi.org/10.1002/JBMR.3888
Del Toro R, Cavallari I, Tramontana F, et al. Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity. Endocrine. 2021;73(2):339-346. https://doi.org/10.1007/s12020-021-02736-8
Barchetta I, Ceccarelli V, Cimini FA, et al. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. J Endocrinol Invest. 2019;42(5):513-520. https://doi.org/10.1007/s40618-018-0941-x
Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C. The role of osteoprotegerin and its ligands in vascular function. Int J Mol Sci. 2019;20(3):705. https://doi.org/10.3390/IJMS20030705
Fadini GP, Albiero M, Menegazzo L, et al. Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. Exp Diabetes Res. 2012;2012:921685-921687. https://doi.org/10.1155/2012/921685
Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175-2180. https://doi.org/10.1161/01.CIR.0000127957.43874.BB
Browner WS, Lui L.-Y, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86(2):631-637. https://doi.org/10.1210/JCEM.86.2.7192
Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161(6):2035-2046. https://doi.org/10.1016/S0002-9440(10)64482-3
Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17(1):20-33. https://doi.org/10.1016/j.cmet.2012.11.012
Barchetta I, Capoccia D, Baroni MG, et al. The “Sapienza university mortality and morbidity event rate (SUMMER) study in diabetes”: study protocol. Nutr Metab Cardiovasc Dis. 2016;26(2):103-108. https://doi.org/10.1016/J.NUMECD.2015.09.009
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470. https://doi.org/10.7326/0003-4819-130-6-199903160-00002
Jann B. Stata Module for Multivariate-Distance and Propensity-Score Matching, Including Entropy Balancing, Inverse Probability Weighting, (Coarsened) Exact Matching, and Regression Adjustment; 2017. Accessed 18 November 2022. https://ideas.repec.org/c/boc/bocode/s458346.html
Maddaloni E, D’Onofrio L, Lauria A, et al. Osteocalcin levels are inversely associated with Hba1c and BMI in adult subjects with long-standing type 1 diabetes. J Endocrinol Invest. 2014;37(7):661-666. https://doi.org/10.1007/s40618-014-0092-7
Seidu S, Kunutsor SK, Khunti K. Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis. Scand Cardiovasc J, 2019;53(6):286-295, https://doi.org/10.1080/14017431.2019.1655166
Darwish L, Nguyen MM, Saleem M, et al. Lower serum osteocalcin concentrations in patients with type 2 diabetes and relationships with vascular risk factors among patients with coronary artery disease. J Diabetes Complicat. 2019;33(5):390-397. https://doi.org/10.1016/J.JDIACOMP.2019.01.003
Sanchez-Enriquez S, Ballesteros-Gonzalez IT, Villafán-Bernal JR, et al. Serum levels of undercarboxylated osteocalcin are related to cardiovascular risk factors in patients with type 2 diabetes mellitus and healthy subjects. World J Diabetes. 2017;8(1):11. https://doi.org/10.4239/WJD.V8.I1.11
Pieralice S, Vigevano F, Del Toro R, Napoli N, Maddaloni E. Lifestyle management of diabetes: implications for the bone-vascular Axis. Curr Diab Rep. 2018;18(10):84. https://doi.org/10.1007/s11892-018-1060-y
Ma H, Lin H, Hu Y, et al. Serum levels of osteocalcin in relation to glucose metabolism and carotid atherosclerosis in Chinese middle-aged and elderly male adults: the Shanghai Changfeng Study. Eur J Intern Med. 2014;25(3):259-264. https://doi.org/10.1016/J.EJIM.2014.01.017
Gordin D, Soro-Paavonen A, Thomas MC, et al. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care. 2013;36(7):1827-1833. https://doi.org/10.2337/dc12-2170
Yu G, Ji X, Jin J, Bu S. Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy. Ann Clin Biochem. 2015;52(2):232-236. https://doi.org/10.1177/0004563214533669
Abu El-Asrar AM, Ahmad A, Alam K, et al. Unbalanced vitreous levels of osteoprotegerin, RANKL, RANK, and TRAIL in proliferative diabetic retinopathy. Ocular Immunol Inflamm. 2017;26(8):1248-1260. https://doi.org/10.1080/09273948.2017.1343855
Zhang X, Chee WK, Liu S, et al. Association of plasma osteopontin with diabetic retinopathy in Asians with type 2 diabetes. Mol Vis. 2018;24:165.